menu
    • menu
    [{"orgOrder":0,"company":"Incendia Therapeutics","sponsor":"XtalPi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Incendia Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incendia Therapeutics \/ Incendia Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Incendia Therapeutics \/ Incendia Therapeutics"},{"orgOrder":0,"company":"Incendia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"PRTH-101","moa":"DDR1","graph1":"Oncology","graph2":"Phase I","graph3":"Incendia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incendia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Incendia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Incendia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||DDR1","graph1":"Oncology","graph2":"Phase I","graph3":"Incendia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incendia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Incendia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Incendia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||DDR1","graph1":"Oncology","graph2":"Phase I","graph3":"Incendia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incendia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Incendia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Incendia Therapeutics","sponsor":"ImaginAb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"PRTH-101","moa":"DDR1","graph1":"Oncology","graph2":"Preclinical","graph3":"Incendia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incendia Therapeutics \/ Incendia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Incendia Therapeutics \/ Incendia Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Incendia Therapeutics

    Menu

    Incendia Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Incendia Therapeutics

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Incendia Therapeutics

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PRTH-101,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Incendia Therapeutics Enrolls First Patient in Ph 1c Trial of PRTH-101, a DDR1 Inhibitor

                            Details : PRTH-101 is a novel DDR1 antagonist mAb, expressed at very high levels in solid tumors with low levels of T cell infiltration, it is being studied for the treatment of immune-excluded solid tumors.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            October 09, 2024

                            Lead Product(s) : PRTH-101,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Incendia Therapeutics

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Incendia Therapeutics

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : XtalPi

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            XtalPi and Parthenon Enter into AI-Powered Antibody Discovery Partnership

                            Details : Under this agreement, XtalPi will grant Parthenon Therapeutics access to its proprietary XupremAb™ antibody discovery platform, which is a collection of solutions that leverage AI and wet lab techniques to deliver therapeutic antibody candidates.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 09, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : XtalPi

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Incendia Therapeutics

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Incendia Therapeutics

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PRTH-101,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Parthenon Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of PRTH-101, a Novel DDR1 Inhib...

                            Details : PRTH-101 is a novel discoidin domain receptor 1 (DDR1) antagonist monoclonal antibody that is expressed at very high levels in solid tumors with low levels of T cell infiltration, it is being investiated for the treatment of immune-excluded solid tumors.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            April 25, 2023

                            Lead Product(s) : PRTH-101,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Incendia Therapeutics

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Incendia Therapeutics

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PRTH-101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            March 03, 2023

                            Lead Product(s) : PRTH-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Incendia Therapeutics

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Incendia Therapeutics

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PRTH-101

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : ImaginAb

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Parthenon Therapeutics and ImaginAb Announce License and Supply Agreement to Advance New Class of Anti-Cancer ...

                            Details : Parthenon will use ImaginAb’s CD8 ImmunoPET imaging agent 89Zr crefmirlimab berdoxam in its Phase 1 trial evaluating its lead compound, PRTH-101, which is expected to begin in 2023.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            October 11, 2022

                            Lead Product(s) : PRTH-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : ImaginAb

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth